Detection of elevated IL-8 and TNF-α levels later than 6 months from acute COVID-19 disease may help to identify patients at increased risk of late venous thromboembolism; nevertheless, further studies are needed to validate this observation.
Key Findings
Results
VTE was diagnosed in 39.8% of 108 symptomatic post-COVID-19 patients, with 16.7% occurring during COVID-19 and 23.1% after the acute phase.
108 consecutive patients (69 males, 63.9%; 39 females, 36.1%) were admitted to a single lung disease department of a tertiary hospital for sustained dyspnea and/or exercise intolerance.
VTE included pulmonary embolism and/or deep vein thrombosis confirmed by standard imaging.
All patients had objectively confirmed prior SARS-CoV-2 infection.
Results
Median D-dimer was higher in patients with VTE within 6 months of COVID-19 diagnosis than in non-VTE patients, with borderline significance.
607 ng/mL vs. 428 ng/mL, p = 0.0595.
Analysis compared patients who entered the study ≤6 months versus >6 months from acute infection.
Results
Median IL-8 was significantly higher in patients who developed VTE more than 6 months after COVID-19 than in non-VTE patients.
10.19 pg/mL vs. 6.61 pg/mL, p = 0.048.
Applies to the subgroup studied >6 months from acute COVID-19.
Results
Median TNF-α was significantly higher in patients with late VTE (>6 months after COVID-19) than in non-VTE patients.
39.02 pg/mL vs. 24 pg/mL, p = 0.011.
Results
TNF-α concentration had the best diagnostic utility for VTE prediction in symptomatic patients diagnosed >6 months from acute infection.
ROC AUC 0.73, 95% CI 0.57-0.91.
Other measured markers (IL-1β, IL-6, IL-10, PAI-1, ferritin) were also assessed; TNF-α gave the best utility.
Results
TNF-α was an independent risk factor for VTE episodes in the whole study group.
Finding applies to the entire cohort of 108 patients.
Authors state further studies are needed to validate the observation.
What This Means
This study looked at 108 people who still had breathlessness or poor exercise tolerance after having COVID-19 and were treated at a lung disease hospital department. About 4 in 10 (39.8%) had a venous blood clot, such as a clot in the lungs or legs; some occurred during the COVID-19 illness and others afterward.
The researchers measured inflammation-related proteins in the blood. In people examined more than 6 months after COVID-19, those who had a clot had higher levels of IL-8 and TNF-α than those without. TNF-α was the best of the markers at distinguishing patients with clots in this later group, with moderate accuracy (AUC 0.73), and was linked to clots in the whole group independently of other factors. D-dimer, a common clot-related test, was only borderline higher in those with clots within 6 months.
This research suggests that persistent inflammation might help identify people at higher risk of late clots after COVID-19. However, the study was from a single center with a small sample, so the findings need to be confirmed in larger studies before they can be used in practice.
Wyrostkiewicz D, Lewandowska K, Jankowska E, Dybowska M, Jędrych M, Zimna K, et al.. (2026). TNF-α and IL-8 Are Helpful in the Prediction of Late Post-COVID-19 Venous Thromboembolic Disease-Single-Center Prospective Study.. International journal of molecular sciences. https://doi.org/10.3390/ijms27209281